Amicus Therapeutics Inc (FOLD) concluded trading on Thursday at a closing price of $6.51, with 4.93 million shares of worth about $32.1 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -35.16% during that period and on April 10, 2025 the price saw a loss of about -5.52%. Currently the company’s common shares owned by public are about 299.04M shares, out of which, 296.87M shares are available for trading.
Stock saw a price change of -18.62% in past 5 days and over the past one month there was a price change of -26.77%. Year-to-date (YTD), FOLD shares are showing a performance of -30.89% which decreased to -44.60% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.20 but also hit the highest price of $12.65 during that period. The average intraday trading volume for Amicus Therapeutics Inc shares is 2.73 million. The stock is currently trading -20.61% below its 20-day simple moving average (SMA20), while that difference is down -26.75% for SMA50 and it goes to -35.40% lower than SMA200.
Amicus Therapeutics Inc (NASDAQ: FOLD) currently have 299.04M outstanding shares and institutions hold larger chunk of about 97.65% of that.
The stock has a current market capitalization of $2.00B and its 3Y-monthly beta is at 0.67. It has posted earnings per share of -$0.18 in the same period. It has Quick Ratio of 2.60 while making debt-to-equity ratio of 2.29. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for FOLD, volatility over the week remained 9.85% while standing at 4.64% over the month.
Stock’s fiscal year EPS is expected to rise by 115.91% while it is estimated to increase by 1061.68% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on December 13, 2024 offering an Equal-weight rating for the stock and assigned a target price range of between $17 and $12 to it. Coverage by Jefferies stated Amicus Therapeutics Inc (FOLD) stock as a Buy in their note to investors on September 06, 2024, suggesting a price target of $18 for the stock. On May 30, 2024, Wells Fargo Initiated their recommendations, while on May 14, 2024, Guggenheim Upgrade their ratings for the stock with a price target of $13. Stock get an Overweight rating from Morgan Stanley on December 19, 2023.
